This is a preview of subscription content, log in via an institution to check access.
Notes
A randomised, multicentre, double-blind, placebo-controlled, phase III trial involving 592 patients comparing golimumab 2mg/kg+MTX with placebo+MTX.
The Health Assessment Questionnaire Disability Index, a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas.
The Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire, that assesses 3 scales of self-reported tiredness.
The 28-joint Disease Activity Score using C-reactive protein.
Reference
Bingham CO 3rd, et al. The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial. The Journal of Rheumatology : May 2014. Available from: URL: http://doi.org/10.3899/jrheum.130864
Rights and permissions
About this article
Cite this article
Golimumab treatment goes further. PharmacoEcon Outcomes News 703, 5 (2014). https://doi.org/10.1007/s40274-014-1255-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1255-7